Header Deubzer
© Hedwig Deubzer, ECRCV, Charite

AG Deubzer

Epigenetische Modifikationen in Neuroblastom

Veröffentlichungen

in Oncotarget

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

V. Arnhold et al.
in Oncotarget

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma

M. Lodrini et al.
in Klin Padiatr

2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors

T. Simon et al.
in Oncotarget

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status

A. Gottlieb et al.
in Am J Med Genet A

Childhood cancer predisposition syndromes - a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology

T. Ripperger et al.
in Cell Death Dis

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival

T.M. Thole et al.
in Oncotarget

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models

K.W. Pajtler et al.
in Oncotarget

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma

J. Fabian et al.
in J Proteome Res

Minichromosome maintenance complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells

M. Lodrini et al.
in Acta Neuropathol Commun

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma

J. Ecker et al.
Porträt Hedwig Deubzer

PD Dr. Hedwig Deubzer

 

Contact:

hedwig.deubzer@charite.de

 

Experimental & Clinical Research Center

Lindenberger Weg 80

13125 Berlin

 

Building 49